Madrigal Pharmaceuticals, Inc.

MDGLNASDAQHealthcare● Active

$486.98

$-5.85(-1.19%)

Market Cap$11.2B

P/E Ratio—

52W High$615

52W Low$271.96

Avg Volume318K

Open$494.49

Beta-1.06

Cash on Hand Financials Revenue

Madrigal Pharmaceuticals, Inc. (MDGL) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

MDGL · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$983.6M▲ +6.2% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$198.7M

cashAndCashEquivalents

Short-Term Investments

$784.9M

shortTermInvestments

YoY Change vs Prior Year

+6.2%

vs prior fiscal year

Latest Quarter

$817.9M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$983.6MCash on Hand

Total Debt$354.4MTotal Debt

Net Cash / Net Debt+$629.2MNet Cash Position

Cash vs Debt Ratio

Cash 74%Madrigal Pharmaceuticals, Inc. cash as % of market cap: 8.76%% · MCap $11BDebt 26%

Madrigal Pharmaceuticals, Inc. has a net cash position of $629.2M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$983.6M − $354.4M = +$629.2M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

MDGL annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

MDGL cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$983.6M+6.2%

Dec 31, 2024FY$926.3M+46.1%

Dec 31, 2023FY$634.1M+76.7%

Dec 31, 2022FY$358.8M+32.7%

Dec 31, 2021FY$270.3M-4.9%

MDGL cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

MDGL vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Madrigal Pharmaceuticals, Inc.YOU

MDGL

$983.6M$11B8.8%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Madrigal Pharmaceuticals, Inc. (MDGL) cash on hand as of December 31, 2025 is $983.6M, comprising $198.7M in cash and cash equivalents (CCE) plus $784.9M in short-term investments — reported as Madrigal Pharmaceuticals, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Madrigal Pharmaceuticals, Inc. cash reserves or cash position.

Madrigal Pharmaceuticals, Inc. annual cash on hand history shows increased +6.2% in 2025: increased +6.2% in 2025. Madrigal Pharmaceuticals, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Madrigal Pharmaceuticals, Inc. carries total debt of $354.4M against cash of $983.6M, resulting in a net cash position of +$629.2M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

MDGL cash on hand · 5 questions

As of December 31, 2025, Madrigal Pharmaceuticals, Inc. (MDGL) has $983,559,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $198,693,000 in cash and cash equivalents (CCE) plus $784,866,000 in short-term investments. Latest quarter (March 31, 2026): $817,926,000. Data sourced from the annual 10-K filing via FMP.

MDGL cash on handMDGL cash reservesMDGL cash 2025how much cash does MDGL have

▸ Source: FMP /balance-sheet-statement · US GAAP · Madrigal Pharmaceuticals, Inc. · Madrigal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025